FOR IMMEDIATE RELEASE — 11 March 2026
Parvovirus B19 Infection in Pregnancy: Perinatal Outcomes & How to Overcome Risks — Learnings from Dr. Megha Khanna

Raising Awareness Across All News Channels
Kolkata, India — Parvovirus B19 is a common viral infection that, when acquired during pregnancy, can be transmitted across the placenta and potentially affect fetal health. While many infections are mild or asymptomatic in pregnant women, maternal infection has been associated with increased risks of adverse outcomes including fetal loss, spontaneous abortion, and stillbirth. A systematic review and meta-analysis of multiple studies found that maternal Parvovirus B19 infection significantly increased the risk of these negative perinatal outcomes compared with uninfected pregnancies. Specifically, the incidence of fetal loss and non‑immune hydrops fetalis in infected pregnancies was notable, with hydrops identified as a key factor associated with mortality and poorer fetal outcomes.
Transplacental passage of Parvovirus B19 occurs in an estimated 17–33% of maternal infections, with the highest transmission risk during early to mid‑pregnancy. Although many fetuses remain asymptomatic and recover spontaneously, those that develop severe anemia, hydrops fetalis, or cardiac complications may face significant health challenges. Ultrasound findings such as fetal fluid accumulation and Doppler blood flow changes are important markers used in clinical monitoring to detect complications early.
Protecting Pregnancy: Clinical Management and Awareness

There is currently no vaccine available to prevent Parvovirus B19 infection, making prevention through exposure reduction critically important. Pregnant women who are exposed to individuals with symptoms of Parvovirus B19, such as rash or joint pain, should promptly consult a healthcare provider for assessment and appropriate testing. Serologic testing for IgG and IgM antibodies helps determine whether the infection is recent, past, or if immunity is already present, which can provide reassurance about pregnancy risk.
Management of confirmed maternal infection includes close monitoring of the pregnancy with serial ultrasounds every 1–2 weeks for up to 12 weeks. These assessments include Doppler measurement of the middle cerebral artery peak systolic velocity to identify fetal anemia — a key indicator of possible complications. In cases of moderate to severe fetal anemia or hydrops, referral to a specialist center for advanced care such as intrauterine blood transfusion may be necessary to support fetal well‑being.
Important Advice from Dr. Megha Khanna

According to Dr. Megha Khanna, one of the leading lady gynecologists in Kolkata, awareness and early action are essential in mitigating the risks associated with Parvovirus B19 in pregnancy. She emphasizes the importance of educating pregnant women about avoiding exposure, recognizing symptoms, and seeking timely medical care. “Most women exposed to Parvovirus B19 will not develop serious complications, especially if immunity is present. However, early detection and monitoring can make a significant difference for those at risk,” Dr. Khanna explains. Regular prenatal care and open communication with healthcare providers are key to ensuring optimal outcomes.

Take‑Home Messages for the Public
• Parvovirus B19 infection in pregnancy can increase the risk of fetal complications, though many infections resolve without adverse effects.

• Pregnant women with known exposure or symptoms should seek immediate evaluation and serologic testing.

• Close monitoring with ultrasounds and Doppler studies can identify early signs of fetal anemia or hydrops and guide timely interventions.

• There is no vaccine; reducing exposure through hygiene and avoiding contact with infected individuals is critical.

As part of ongoing public health efforts, medical professionals encourage all pregnant women to prioritize prenatal care and stay informed about infectious risks that can affect pregnancy. For expert guidance and care, patients in Kolkata and surrounding regions can consult trusted obstetric specialists including Dr. Megha Khanna for personalized evaluation and support.


Media Contact:
Press Office
[Dr Megha Khanna]
Date: 11 March 2026